HIV-specific T cells generated from HIV-naive adult and cord blood donors target a range of novel viral epitopes: implications for a cure strategy after allogeneic HSCT and CBT

• S. Patel,
• R.B. Jones,
• E. Shpall,
• D. Margolis,
• C.M. Bollard,
• E. Williams,
• S. Albihani,
• S. Lam,
• J. A.M. Sung,
• C. Russell Cruz,
• R.F. Ambinder

Affiliations

S. Patel

Center for Cancer and Immunology Research, Children's National Health System, Washington, DC, USA; Microbiology, Immunology, and Tropical Medicine, The George Washington University, Washington DC, USA

R.B. Jones

Microbiology, Immunology, and Tropical Medicine, The George Washington University, Washington DC, USA

E. Shpall

University of North Carolina HIV Cure Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

D. Margolis

University of North Carolina HIV Cure Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

C.M. Bollard

Center for Cancer and Immunology Research, Children's National Health System, Washington, DC, USA; Microbiology, Immunology, and Tropical Medicine, The George Washington University, Washington DC, USA

E. Williams

Center for Cancer and Immunology Research, Children's National Health System, Washington, DC, USA

S. Albihani

Center for Cancer and Immunology Research, Children's National Health System, Washington, DC, USA

S. Lam

Center for Cancer and Immunology Research, Children's National Health System, Washington, DC, USA

J. A.M. Sung

University of North Carolina HIV Cure Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

C. Russell Cruz

Center for Cancer and Immunology Research, Children's National Health System, Washington, DC, USA; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

R.F. Ambinder

Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA